An estimated 65 million people worldwide live with Long COVID. Fatigue, brain fog, POTS, and exercise intolerance are among the most debilitating symptoms — and they share a common thread: vascular and endothelial dysfunction. EECP addresses these mechanisms directly, and early clinical data is promising.
EECP is FDA-cleared for cardiac conditions (angina, heart failure). Its use for Long COVID is off-label — legal, supported by emerging evidence, but not part of the FDA-cleared labeling. The evidence base is early-stage; larger randomized trials are underway. Always consult your physician before starting any new therapy.
Long COVID — defined as symptoms persisting more than 12 weeks after acute SARS-CoV-2 infection — affects an estimated 10–30% of COVID-19 survivors. The most common symptoms include fatigue, post-exertional malaise (PEM), cognitive impairment ("brain fog"), dysautonomia, and exercise intolerance. Despite affecting tens of millions of people, effective treatments remain limited.
Research published in Nature Reviews Cardiology and other leading journals has established endothelial dysfunction as a central feature of Long COVID. SARS-CoV-2 directly infects endothelial cells via ACE2 receptors, causing persistent inflammation, microclot formation, and impaired nitric oxide production — the same pathological process that underlies coronary artery disease and heart failure.
EECP is one of the most powerful non-pharmacological interventions for endothelial dysfunction known to medicine. It increases shear stress on endothelial cells, upregulates nitric oxide synthase (eNOS), reduces inflammatory cytokines, and stimulates new blood vessel growth. These are precisely the mechanisms that Long COVID researchers have identified as therapeutic targets — which is why a growing number of EECP providers are offering it for Long COVID patients.
EECP's vascular and endothelial effects map onto several proposed Long COVID mechanisms.
EECP improves oxygen delivery to skeletal muscle and reduces the metabolic cost of exertion by increasing cardiac output and peripheral perfusion. Patients with Long COVID often have reduced cardiac reserve — EECP addresses this directly.
Postural orthostatic tachycardia syndrome (POTS) is common in Long COVID and involves impaired autonomic regulation of blood flow. EECP's shear-stress-mediated improvements in vascular tone and baroreflex sensitivity may help stabilize autonomic function.
Long COVID patients often show reduced VO2 max and impaired cardiac output during exercise. EECP acts as a form of passive cardiovascular conditioning, improving cardiac efficiency and peripheral oxygen extraction without requiring the patient to exercise.
Cerebral microvascular dysfunction has been identified in Long COVID patients. EECP's improvements in cerebral blood flow and endothelial function — the same mechanism that benefits dementia patients — may address the vascular component of Long COVID cognitive symptoms.
Mitochondrial dysfunction and reduced ATP production are implicated in Long COVID fatigue. EECP increases oxygen delivery to all tissues, supporting mitochondrial function and cellular energy production throughout the body.
Long COVID patients often cannot tolerate exercise. EECP delivers cardiovascular conditioning without requiring physical exertion — ideal for patients with post-exertional malaise (PEM).
Long COVID is multi-system. EECP's effects on endothelial function, autonomic regulation, cerebral blood flow, and oxygen delivery address several proposed Long COVID mechanisms simultaneously.
Many Long COVID patients are already on multiple medications. EECP is non-pharmacological and has no known drug interactions, making it safe to add to existing treatment protocols.
EECP has been used in over 100,000 patients for cardiac indications with an excellent safety profile. This established record makes it a lower-risk option for Long COVID patients compared to experimental pharmacological approaches.
The evidence base for EECP in Long COVID is early but growing. Here is what has been published to date.
Frontiers in Cardiovascular Medicine
A pilot study of 20 Long COVID patients with persistent fatigue and exercise intolerance completed 35 sessions of EECP. Significant improvements were observed in 6-minute walk distance, fatigue scores (Chalder Fatigue Scale), and quality of life measures. No adverse events were reported. The authors called for larger randomized trials.
Nature Reviews Cardiology
Comprehensive review establishing that endothelial dysfunction is a central feature of Long COVID, affecting multiple organ systems. The authors propose that therapies targeting endothelial function — including EECP — represent a rational treatment approach for Long COVID's multi-system symptoms.
Journal of Neurological Sciences
Transcranial Doppler studies showed significant improvements in cerebral blood flow velocity after EECP in patients with cognitive complaints. Given that cerebral microvascular dysfunction is a proposed mechanism of Long COVID brain fog, these findings suggest EECP may benefit Long COVID cognitive symptoms.
Clinical Cardiology
EECP was shown to improve heart rate variability (HRV) and baroreflex sensitivity in cardiac patients — both markers of autonomic function. Given that dysautonomia and POTS are among the most debilitating Long COVID symptoms, EECP's autonomic effects are of particular interest for this population.
No Provider Nearby?
Some Long COVID patients travel to complete an intensive course. Learn about travel-for-treatment options including 2 sessions/day programs.
Not all EECP providers offer treatment for Long COVID. Use our directory to find providers in your state, then check their individual listing to see which conditions they treat. Our grading system rewards providers who offer EECP for the full range of indications.
FDA-cleared for chronic stable angina — the primary cardiac indication.
FDA-cleared for heart failure — mechanism, evidence, and who qualifies.
Peripheral artery disease — Fontaine staging, evidence, and provider guide.
Peer-reviewed research on EECP for 20+ conditions.